RxDoctor Payments Data

Lenia Prinos, NP

Family · Langhorne, PANPI 1407192263

Payments from drug & device makers

$2,195in general payments, 2019–2025

Across 26 payments — averaging $84.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$329
  • Amgen$283
  • Boehringer Ingelheim$243
  • E.r. Squibb & Sons, L.L.C.$202
  • Insmed, Inc.$187
  • Johnson & Johnson$132
  • plus $819 from 9 others

What the payments were for

  • Food & beverage$2,195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,195 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,225
Medicare patients
27
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$14,490
JanuviaSitagliptin Phosphate26$8,083
EliquisApixaban25$7,885
JardianceEmpagliflozin22$7,322
Gabapentin42$1,273
Pantoprazole Sodium34$1,162
Atorvastatin Calcium24$677
Metformin Hcl21$672
Fluticasone Propionate21$571
Duloxetine Hcl17$439
Lisinopril21$432
Levothyroxine Sodium17$390
Metoprolol Succinate13$371
Metoprolol Tartrate26$345
Ezetimibe12$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$243$7,32222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →